Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats

Abstract

Isradipine (ID), is an antihypertensive drug, having low oral bioavailability (15–24%) due to poor aqueous solubility (0.01 mg/mL) and also hepatic first-pass metabolism. Among various approaches, Solid lipid nanoparticles (SLNs) were developed using stearic acid, glyceryl monostearate as lipid matrices for improving the oral bioavailability of ID. ID-SLNs were prepared by using hot homogenization followed by ultrasonication. The prepared SLNs were characterized for size, PDI, zeta potential (ZP), entrapment efficiency (EE) and drug content. In vitro release studies were performed in 0.1NHCl and pH 6.8 phosphate buffer of by open tube method. Physical stability of the SLNs was observed at refrigerated temperature and room temperature for 90 days. Further, pharmacodynamic study was conducted in wistar rats. SLNs prepared with GMS having size of 188.6±3.6 nm, PDI of 0.273±0.052, ZP of − 21.8±2.7 mV with 86.86±0.75% EE were optimized. Differential scanning calorimetric (DSC) study revealed that no interaction between drug and lipid. In vitro release studies showed that more cumulative release of ID in pH 6.8 phosphate buffer than in 0.1NHCl during 24 h. The lyophilized SLN formulation was used in knowing morphology of SLNs, and was found to have spherical shape with increased polydispersity by Scanning electron microscopy. Pharmacodynamic study of SLNs in fructose induced hypertensive rats showed a decrease in systolic blood pressure for 36 h, when compared to suspension, which showed a decrease in systolic blood pressure for only 2 h. Thus, the results conclusively demonstrated the role of SLNs for a significant enhancement in pharmacodynamic effect of ID.

• References

• 1 Amidon GL, Lennernas H, Shah VP, Crison JR.. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420
• 2 Chaumeil JC.. Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find Exp Clin Pharmacol 1998; 20: 211-5
• 3 Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deli Rev 2007; 59: 617-630
• 4 Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J.. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010; 1: 518-527
• 5 Rangel-Yagui CD, Pessoa A, Tavares LC.. Micellar solubilization of drugs. J Phar Pharmac Sci 2005; 8: 147-163
• 6 Uekama K, Hirayama F, Irie T.. Cyclodextrin drug carrier systems. Chem Rev 1998; 98: 2045-2076
• 7 Rogers TL, Hu J, Yu Z, Johnston KP, Williams RO.. A novel particle engineering technology: spray-freezing into liquid. Int J Pharm 2002; 242: 93-100
• 8 Cao F, Guo J, Ping Q.. The physicochemical characteristics of freeze-dried scutellarin- cyclodextrin tetra component complexes. Drug Dev Ind Pharm 2005; 31: 747-756
• 9 Dahan Arik, Hoffman Amnon. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Contr Rel 2008; 129: 1-10
• 10 Üner M, Yener G.. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nano 2007; 2: 289-300
• 11 Mehnert W, Mäder K.. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deli Rev 2012; 47: 165-196
• 12 Mühlen AZ, Schwarz C, Mehnert W.. Solid lipid nanoparticles (SLN) for controlled release drug delivery – drug release and release mechanism. Eur J Pharm Biopharm 1998; 45: 149-155
• 13 Müller RH, Mehnert W, Lucks JS.. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995; 41: 62-69
• 14 Müller RH, Mehnert W, Sven G.. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177
• 15 Souto EB, Almeida AJ, Müller RH.. Lipid Nanoparticles (SLN, NLC) for cutaneous drug delivery: structure, protection and skin effects. J Biomed Nanotech 2007; 3: 317-331
• 16 Chrysant SG, Cohen M.. Long-term antihypertensive effects with chronic administration of isradipine controlled release. Curr Ther Res 1997; 58: 1-9
• 17 Narendar D, Kishan V.. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 2016; 23: 395-404
• 18 Arjun N, Kishan V.. Preparation, characterization and evaluation of quetiapine fumarate solid lipid nanoparticles to improve the oral bioavailability. J Pharmc 2013; 1-7
• 19 Venkateswarlu V, Manjunath K.. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Rel 2004; 95: 627-638
• 20 Manjunath K., Venkateswarlu V.. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Contr Rel 2005; 107: 215-228
• 21 Cavalli R, Caputo O, Carlotti M, Trotta M, Scarnecchia C, Gasco MR.. Sterilization and freeze-drying of drug-free and drug loaded solid lipid nanoparticles. Int J Pharm 1997; 148: 47-54
• 22 Dudhipala N, Veerabrahma K.. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug Dev Ind Pharm 2015; 41: 1968-77
• 23 Dai S, McNeill JH.. Fructose-induced hypertension in rats is concentration-and duration-dependent. J Pharmacol Toxicol Methods 1995; 33: 101-107
• 24 Suvarna G, Narender D, Kishan V.. Preparation, Characterization and In vivo Evaluation of Rosuvastatin Calcium Loaded Solid Lipid Nanoparticles. Int J Pharm Sci Nanotech 2015; 9: 2779-2785
• 25 Montenegro L, Sarpietro MG, Ottimo S, Puglisi G, Castelli F.. Differential scanning calorimetry studies on sunscreen loaded solid lipid nanoparticles prepared by the phase inversion temperature method. Int J Pharm 2011; 415: 301-306
• 26 Choi MJ, Briancon S, Andrieu J, Min SG, Fessi H.. Effect of freeze-drying process conditions on the stability of nanoparticles. Dry Tech 2004; 22: 335-346
• 27 Hwang IS, Ho H, Hoffman BB, Reaven GM.. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512-516
• 28 Rabea Parveen FJ, Ahmad Z, Iqbal MS. Sayeed Ahmad. Effect of andrographolide solid lipid nanoparticles (slns) on breast cancer. Planta Med 2013; 79-105
• 29 Rawat MK, Jain A, Singh S.. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J Pharm Sci 2011; 100: 2366-2378
• 30 Righeschi C, Bergonzi M, Isacchi B, Bilia A.. Solid lipid nanoparticles for oral delivery of Curcumin. Planta Med 2013; 13: 79-84